Close Menu
    Facebook X (Twitter) Instagram
    Trending
    • America’s Longest Shutdown: 43 Days That Closed the Federal Government
    • The First CRISPR Medicine Rewrites the Treatment of Sickle Cell Disease
    • Amazon Deforestation Falls to Its Lowest Level Since 1988
    • Assisted Dying in England and Wales: A Bill That Passed, Fell, and Failed Again
    • Binance Plans Asia Expansion After Record Crypto Heist
    • The Atlantic Current That Warms Europe Is Slowing Down
    • UN Nations Debate Ban on Autonomous Weapons
    • Elephants Remember Friends They Have Not Seen in Years
    MagazineGrace
    • Home
    • News
    • Lifestyle
    • Travel
    • Artificial Intelligence
    • Finance
    MagazineGrace
    Home»News

    The First CRISPR Medicine Rewrites the Treatment of Sickle Cell Disease

    Eino KorhonenBy Eino KorhonenNovember 21, 2026 News No Comments3 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr Email
    Red blood cells seen under a microscope.

    In December 2023, regulators in the United States approved the first medicine based on CRISPR gene editing, a treatment for sickle cell disease called Casgevy. Sickle cell disease is caused by a single faulty gene that makes red blood cells stiff and crescent-shaped, blocking blood vessels and causing severe pain, organ damage and early death. Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, works by taking a patient’s own blood stem cells, editing them in the laboratory to switch off a gene called BCL11A, and returning them to the patient. Switching off that gene reactivates the production of foetal haemoglobin, the form of the oxygen-carrying protein babies make before birth, which does not sickle. The US Food and Drug Administration approved it on 8 December 2023, and Britain and the European Union followed, with England’s NHS agreeing a deal for eligible patients in August 2024.

    What the Evidence Shows

    The approval is a landmark for genetic medicine, because it proves that editing a patient’s own DNA can treat a disease, not just in theory but in practice. In trials, most treated patients went at least a year without the painful crises that define sickle cell disease, and many remained free of them for far longer. But the treatment is also a test of whether such medicine can reach the people who need it. It costs about 2.2 million dollars per patient, requires months of preparation including chemotherapy to clear the bone marrow, and can only be given in specialist centres. Sickle cell disease affects millions of people, most of them in sub-Saharan Africa, where the treatment is currently out of reach. The science has arrived; the challenge now is making it affordable and available. Reporting and analysis from sources such as Nature track the same developments, and specialists following first CRISPR medicine Casgevy say the direction is now consistent across independent lines of evidence.

    The Wider Context

    The wider context is a research landscape in which replication and open data now decide reputations. Findings connected to first CRISPR medicine Casgevy are being checked by independent groups with shared datasets, and the teams involved publish their methods in full so rivals can test every step. That discipline is slower than a headline cycle, but it is why results in this area increasingly survive first contact with scrutiny.

    What Happens Next

    What happens next in the story of first CRISPR medicine Casgevy will be decided by follow-up work already under way: larger samples, longer observation and instruments that have not yet come online. The researchers involved are unusually united on one point, that the current results justify the next investment of time and money. Readers will not have to wait long for the first tests of that claim. You can follow related developments in our coverage of science.

    None of this will be settled by a single announcement, study or product launch. The pattern to watch is accumulation: independent confirmations, honest reporting of failures and steady improvement in the underlying numbers. Readers who follow those signals, rather than the loudest claim of the week, will understand this subject better than most of the commentary surrounding it suggests is possible.

    CRISPR gene therapy sickle cell disease
    Eino Korhonen

    Keep Reading

    America’s Longest Shutdown: 43 Days That Closed the Federal Government

    Amazon Deforestation Falls to Its Lowest Level Since 1988

    Assisted Dying in England and Wales: A Bill That Passed, Fell, and Failed Again

    Binance Plans Asia Expansion After Record Crypto Heist

    The Atlantic Current That Warms Europe Is Slowing Down

    UN Nations Debate Ban on Autonomous Weapons

    Add A Comment
    Leave A Reply Cancel Reply

    Search
    Recent Posts

    America’s Longest Shutdown: 43 Days That Closed the Federal Government

    November 21, 2026

    The First CRISPR Medicine Rewrites the Treatment of Sickle Cell Disease

    November 21, 2026

    Amazon Deforestation Falls to Its Lowest Level Since 1988

    November 20, 2026

    Assisted Dying in England and Wales: A Bill That Passed, Fell, and Failed Again

    November 20, 2026

    Binance Plans Asia Expansion After Record Crypto Heist

    November 19, 2026

    The Atlantic Current That Warms Europe Is Slowing Down

    November 19, 2026
    About Us

    MagazineGrace hub for Tech, Travel, Lifestyle & Innovation bringing latest tech trends, travel inspiration, lifestyle tips, global innovation, creativity, modern living insights.

    Platform connecting curious minds with ideas shaping future, empowering exploration, innovation, stylish living in digital era.

    Facebook X (Twitter) Instagram Reddit TikTok
    Popular Posts

    America’s Longest Shutdown: 43 Days That Closed the Federal Government

    November 21, 2026

    The First CRISPR Medicine Rewrites the Treatment of Sickle Cell Disease

    November 21, 2026

    Amazon Deforestation Falls to Its Lowest Level Since 1988

    November 20, 2026
    Contact Us

    If you have any questions or need further information, feel free to reach out to us at

    Email: lesley.official47@gmail.com
    Phone: +92 345 1956410

    Address: 2708 Hog Camp Road
    Wheeling, IL 60090

    Copyright © 2026 | All Rights Reserved | MagazineGrace
    • About Us
    • Contact Us
    • Disclaimer
    • Terms & Conditions
    • Privacy Policy
    • Write For Us
    • Sitemap

    Type above and press Enter to search. Press Esc to cancel.

    WhatsApp us